Profile data is unavailable for this security.
About the company
ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the commercialization and development of neffy for the needle-free intranasal delivery of epinephrine for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an innovative absorption enhancer called Intravail, which allows neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
- Revenue in USD (TTM)142.77m
- Net income in USD-80.04m
- Incorporated2016
- Employees162.00
- LocationARS Pharmaceuticals Inc11682 El Camino Real, Suite 300SAN DIEGO 92130United StatesUSA
- Phone+1 (858) 771-9307
- Fax+1 (302) 636-5454
- Websitehttps://ars-pharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arvinas Inc | 262.60m | -80.80m | 856.44m | 246.00 | -- | 1.96 | -- | 3.26 | -1.22 | -1.22 | 3.70 | 6.83 | 0.2903 | -- | 78.39 | 1,067,480.00 | -8.93 | -18.57 | -11.25 | -22.95 | -- | -- | -30.77 | -141.50 | -- | -- | 0.0009 | -- | -0.3037 | 64.50 | 59.38 | -- | -21.68 | -- |
| Sellas Life Sciences Group Inc | 0.00 | -25.94m | 859.92m | 15.00 | -- | 13.84 | -- | -- | -0.2869 | -0.2869 | 0.00 | 0.3648 | 0.00 | -- | -- | 0.00 | -66.47 | -125.08 | -84.33 | -231.32 | -- | -- | -- | -1,399.79 | -- | -- | 0.00 | -- | -- | -- | 17.30 | -- | -- | -- |
| SS Innovations International Inc | 33.57m | -17.11m | 871.30m | 378.00 | -- | 21.97 | -- | 25.95 | -0.0959 | -0.0959 | 0.1822 | 0.2048 | 0.6253 | 1.19 | 5.09 | 88,820.32 | -31.86 | -77.47 | -50.87 | -137.45 | 48.25 | 23.69 | -50.96 | -169.09 | 1.34 | -- | 0.2025 | -- | 251.46 | -- | 8.27 | -- | 67.53 | -- |
| Arbutus Biopharma Corp | 14.61m | -42.28m | 898.15m | 44.00 | -- | 11.58 | -- | 61.49 | -0.2219 | -0.2219 | 0.0764 | 0.4032 | 0.1227 | -- | 11.62 | 331,954.50 | -35.50 | -44.03 | -39.50 | -49.46 | -- | -- | -289.45 | -433.59 | -- | -- | 0.0454 | -- | -65.98 | 0.5268 | 4.02 | -- | -20.93 | -- |
| Xencor Inc | 125.58m | -91.92m | 902.07m | 260.00 | -- | 1.39 | -- | 7.18 | -1.24 | -1.24 | 1.69 | 8.84 | 0.1374 | -- | 2.79 | 482,984.60 | -10.08 | -9.90 | -11.18 | -10.89 | -- | -- | -73.37 | -51.10 | -- | -- | 0.1585 | -- | 13.65 | 0.4654 | 60.48 | -- | -25.55 | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 904.79m | 119.00 | 13.26 | 8.21 | 30.88 | 7.96 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 906.34m | 62.00 | -- | 2.81 | -- | 153.18 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 906.44m | 162.00 | -- | 6.14 | -- | 6.35 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Maravai Lifesciences Holdings Inc | 185.74m | -130.77m | 928.01m | 435.00 | -- | 4.35 | -- | 5.00 | -0.9059 | -0.9059 | 1.29 | 0.8296 | 0.2088 | 3.35 | 5.80 | 426,995.40 | -25.95 | 4.29 | -36.49 | 5.56 | 18.30 | 68.51 | -124.24 | 13.71 | 5.69 | -7.54 | 0.4642 | 0.00 | -28.34 | -8.15 | 9.72 | -- | -12.34 | -- |
| MannKind Corp | 348.97m | 6.70m | 935.08m | 592.00 | 157.17 | -- | 49.26 | 2.68 | 0.0193 | 0.0193 | 1.12 | -0.1658 | 0.5885 | 2.45 | 6.56 | 589,469.60 | 1.13 | -7.58 | 1.44 | -9.71 | 77.80 | 70.19 | 1.92 | -14.56 | 1.50 | 1.31 | 1.09 | -- | 22.23 | 39.89 | -78.75 | -- | -0.9285 | -- |
| Cullinan Therapeutics Inc | 0.00 | -216.81m | 944.63m | 111.00 | -- | 2.09 | -- | -- | -3.68 | -3.68 | 0.00 | 7.64 | 0.00 | -- | -- | 0.00 | -38.12 | -16.54 | -40.13 | -17.34 | -- | -- | -- | -1,797.10 | -- | -- | 0.00 | -- | -- | -- | -9.28 | -- | -- | -- |
| Personalis Inc | 69.65m | -81.27m | 947.96m | 260.00 | -- | 3.55 | -- | 13.61 | -0.9088 | -0.9088 | 0.7805 | 2.55 | 0.2305 | 8.92 | 5.72 | 267,876.90 | -26.89 | -30.49 | -30.46 | -34.81 | 22.65 | 27.97 | -116.69 | -118.80 | 6.61 | -- | 0.0197 | -- | -17.69 | -2.40 | 0.0172 | -- | 6.77 | -- |
| Arrivent Biopharma Inc | 0.00 | -151.40m | 956.90m | 52.00 | -- | 3.10 | -- | -- | -4.24 | -4.24 | 0.00 | 7.47 | 0.00 | -- | -- | 0.00 | -48.90 | -- | -51.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.09 | -- | -- | -- |
| CareDx Inc | 379.81m | -21.35m | 960.05m | 761.00 | -- | 3.15 | -- | 2.53 | -0.3943 | -0.3943 | 7.09 | 5.95 | 0.84 | 5.33 | 7.08 | 499,086.70 | -4.72 | -10.84 | -5.89 | -12.94 | 67.55 | 66.23 | -5.62 | -16.52 | 2.56 | -- | 0.00 | -- | 13.79 | 14.59 | -140.64 | -- | -8.66 | -- |
Data as of Mar 03 2026. Currency figures normalised to ARS Pharmaceuticals Inc's reporting currency: US Dollar USD
41.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 31 Dec 2025 | 10.86m | 10.99% |
| Rubric Capital Management LPas of 31 Dec 2025 | 6.20m | 6.27% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.53m | 4.59% |
| abrdn, Inc.as of 31 Dec 2025 | 3.56m | 3.60% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 3.22m | 3.26% |
| Millennium Management LLCas of 31 Dec 2025 | 3.17m | 3.21% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.01m | 3.05% |
| Franklin Advisers, Inc.as of 31 Dec 2025 | 2.54m | 2.57% |
| Tyro Capital Management LLCas of 31 Dec 2025 | 1.99m | 2.02% |
| UBS Securities LLCas of 31 Dec 2025 | 1.96m | 1.98% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
